🔗 Share this article World Health Organization Issues Warning Over Acute Scarcity of Obesity Jabs Under 10% of people eligible to benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its initial recommendations on the drugs. Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for broader and more equitable access to GLP-1 medication. Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The new guidelines recognises that obesity is a chronic disease that can be treated with holistic and continuous care," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are major barriers to widespread availability to the injections that can assist patients in reducing significant body mass, explains the body. GLP-1 Therapy Scarcity Even under the present best projected outlook, the supply of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation encourages countries and companies to increase availability, through measures such as voluntary licensing. Exclusive production rights on a key compound – the primary component of the drug Wegovy – is due to expire in several nations in 2026. How Obesity Injections Work These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so individuals reduce food intake. Individuals commonly start to lose weight in the initial weeks of beginning the weekly injections. Research suggests people may see weight return a year later of halting the treatment, when their typical hunger return. To be above a healthy weight elevates your chance for developing health problems, including diabetes, heart disease, stroke, and certain cancers. Excess weight impacts people in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.
Under 10% of people eligible to benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its initial recommendations on the drugs. Given in excess of 1,000,000,000 people worldwide currently obese, it is advocating for broader and more equitable access to GLP-1 medication. Per estimates, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The new guidelines recognises that obesity is a chronic disease that can be treated with holistic and continuous care," remarked its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are major barriers to widespread availability to the injections that can assist patients in reducing significant body mass, explains the body. GLP-1 Therapy Scarcity Even under the present best projected outlook, the supply of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of those who need them, as stated by the WHO. The recommendation encourages countries and companies to increase availability, through measures such as voluntary licensing. Exclusive production rights on a key compound – the primary component of the drug Wegovy – is due to expire in several nations in 2026. How Obesity Injections Work These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and increase the sense of being full so individuals reduce food intake. Individuals commonly start to lose weight in the initial weeks of beginning the weekly injections. Research suggests people may see weight return a year later of halting the treatment, when their typical hunger return. To be above a healthy weight elevates your chance for developing health problems, including diabetes, heart disease, stroke, and certain cancers. Excess weight impacts people in all nations and was linked to millions of deaths worldwide in 2024, according to the WHO.